ArticleFrontiers in genetics2025
Identification and validation of aging related genes in osteoarthritis.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoarthritis (OA) is a degenerative disease associated with aging. Although an increasing body of research suggests a close relationship between aging and OA, the underlying mechanisms remain unclear. This study explores the relationship between aging related genes (ARGs) and OA, providing potential new targets for understanding the pathogenesis and treatment of OA. Methods: The OA synovial tissue dataset was obtained from the GEO database, and differentially expressed genes (DEGs) were screened. The DEGs were intersected with ARGs to identify differentially expressed aging related genes (DEARGs), which were then subjected to functional enrichment analysis, PPI network analysis, and machine learning algorithms (LASSO and RF) to identify key genes. In addition, a nomogram was constructed based on the key genes to predict OA risk, and its diagnostic value was evaluated using ROC curves. Subsequently, the expression levels of the key genes were validated through qRT-PCR experiments. Finally, the CIBERSORT algorithm was applied to assess the proportion of immune cells and investigate the correlation between the key genes and immune cells. Results: A total of 34 DEARGs were identified. PPI network analysis revealed 12 key DEARGs. Subsequently, LASSO and RF algorithms identified ATF3, KLF4, NFKBIA, and SOD2 as key genes. Based on nomogram and ROC curve analysis, these four key genes demonstrated good diagnostic value. qRT-PCR showed that ATF3, KLF4, NFKBIA, and SOD2 were significantly downregulated in OA. Immune infiltration analysis revealed differences in Plasma cells, T cells follicular helper, Mast cells resting, T cells CD4 memory resting, NK cells activated, Monocytes, and Mast cells activated between the OA group and normal controls. Conclusion: ATF3, KLF4, NFKBIA and SOD2 are identified as novel biomarkers associated with aging in OA and may serve as potential therapeutic targets for OA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.